Adaptimmune Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Adaptimmune Therapeutics CEO'su Ad Rawcliffe, Sep2019 tarihinde atandı, in görev süresi 5.17 yıldır. in toplam yıllık tazminatı $ 2.77M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.4% maaş ve 76.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.1% ine doğrudan sahiptir ve bu hisseler $ 169.21K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.9 yıl ve 9.7 yıldır.
Anahtar bilgiler
Ad Rawcliffe
İcra Kurulu Başkanı
US$2.8m
Toplam tazminat
| CEO maaş yüzdesi | 23.4% |
| CEO görev süresi | 5.2yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 4.9yrs |
| Yönetim Kurulu ortalama görev süresi | 9.7yrs |
Son yönetim güncellemeleri
Recent updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$163m |
| Dec 31 2023 | US$3m | US$650k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$650k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$175m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$4m | US$617k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$140m |
| Dec 31 2020 | US$3m | US$574k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$123m |
| Jun 30 2020 | n/a | n/a | -US$127m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$2m | US$500k | -US$137m |
| Sep 30 2019 | n/a | n/a | -US$144m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$102m |
| Dec 31 2018 | US$1m | US$457k | -US$96m |
| Sep 30 2018 | n/a | n/a | -US$87m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$69m |
| Dec 31 2017 | US$2m | US$444k | -US$70m |
Tazminat ve Piyasa: Ad 'nin toplam tazminatı ($USD 2.77M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).
Tazminat ve Kazançlar: Ad 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Ad Rawcliffe (52 yo)
5.2yrs
Görev süresi
US$2,774,041
Tazminat
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 5.2yrs | US$2.77m | 0.10% $ 169.2k | |
| Co-Founder & Chief Business & Strategy Officer | no data | US$1.18m | 0.12% $ 191.0k | |
| Chief Financial Officer | 4.6yrs | US$1.17m | 0.0063% $ 10.2k | |
| COO & Chief Compliance Officer | 7.7yrs | US$1.22m | 0.064% $ 104.5k | |
| Chief Medical Officer | 4.8yrs | US$1.18m | 0.037% $ 60.2k | |
| Chief Scientific Officer | 2.5yrs | Veri yok | 0.0049% $ 7.9k | |
| VP of Corporate Affairs & Investor Relations | no data | Veri yok | Veri yok | |
| Senior VP & General Council | 9.1yrs | Veri yok | Veri yok | |
| Senior Director of Corporate Communications | no data | Veri yok | Veri yok | |
| Chief Patient Supply Officer | 5.3yrs | US$1.72m | 0.053% $ 86.7k | |
| Senior Vice President of Late Stage Development | 4.9yrs | Veri yok | Veri yok | |
| Chief Commercial Officer | less than a year | US$2.19m | 0.015% $ 24.4k |
4.9yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: ADAP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 5.2yrs | US$2.77m | 0.10% $ 169.2k | |
| Independent Chairman of the Board of Directors | 9.8yrs | US$174.83k | 0% $ 0 | |
| Independent Non-Executive Director | 9.8yrs | US$111.54k | Veri yok | |
| Independent Non-Executive Director | 9.7yrs | US$128.80k | 0.0093% $ 15.2k | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | 6.3yrs | US$117.25k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok |
9.7yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ADAP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.7 yıldır).